# Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

> **NCT05664750** · PHASE3 · COMPLETED · sponsor: **Zhuhai Trinomab Pharmaceutical Co., Ltd.** · enrollment: 675 (actual)

## Conditions studied

- Tetanus

## Interventions

- **DRUG:** TNM002
- **DRUG:** Human tetanus immunoglobulin (HTIG)

## Key facts

- **NCT ID:** NCT05664750
- **Lead sponsor:** Zhuhai Trinomab Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-22
- **Primary completion:** 2023-03-24
- **Final completion:** 2023-07-07
- **Target enrollment:** 675 (ACTUAL)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05664750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05664750, "Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05664750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*